Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

PHILADELPHIA, Pa. and OXFORD, UK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (ADSs) in an underwritten public offering.